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Summary: Background: Large randomized controlled clinical 
trials have established excellent evidence for the most fre-
quent exudative macular diseases (neovascular age-realted 
macular degeneration, macular edema due to diabetes and 
retinal vein occlusions) how to treat with intravitreal vascular 
endothelial growth factor inhibitors. Due to multiple limita-
tions such optimal, best evidence-based treatment is hardly 
manageable in any European country.
Material and Methods: The subsequent overview outlines the 
key factors and their variability throughout Europe that limit the 
chance for adequate patient treatment. To outline the differen-
ces a survey was conducted among European retina specialists.
Among the key limitations for optimal treatment are the drug 
label valid throughout the European Union (EU) for the most 
commonly used approved anti-VEGF drug ranibizumab. 
Below the EU-wide regulations are the national and partly re-
gional restrictions for performing and reimbursing intravitreal 
injections. Further restrictions can be of relevance at the level 
of each institution performing intravitreal injections, inclu-
ding budget restrictions and limitations on the number of in-
jections performed. The results of the survey indicate signifi-
cant differences throughout Europe. 
Results: Among the key differences is the time to the final na-
tional decision on reimbursement, which can take several ye-
ars in some European countries. Further differences exist 
among many countries on who and which institutions can 
conduct intravitreal injections. In most countries this is de-
pendent on the reimbursement through the health care sys-
tem. Especially in eastern European countries, institutions - 
being officially reimbursed for intravitreal injections - are 
submitted to further restrictions such as limited budgets or a 
limited number of injections per year. Additional relevant dif-
ferences exist regarding the requirements for the injection 
room, ranging from just a designated room to a fully equipped 
operating room. This has in addition to safety significant im-
plications on cost and time-efficient patient treatment. The 
reimbursement for the intravitreal injection procedure at ins-
titutions with official reimbursement by the health care sys-
tem varies throughout Europe from about 80 to 600 €. Unfor-
tunately, in many countries the organizational structures and 
incentives have – to the disadvantage of patients and treating 
ophthalmologists – not yet been adopted to the needs of the 
era of intravitreal injections. 
Conclusions: With a growing number of affected and by intra-
vitreal anti-VEGF injections treatable patients there will be an 
increasing pressure on improving access to adequate treat-
ment. More uniformity regarding requirements and reimbur-
sement throughout Europe is desirable. Unfortunately a 
further trend to regionalization is observed. 
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Die intravitreale Injektion: Unterschiedliche 
Vorgaben, Kosten und Kostenerstattung in 
Europa
Zusammenfassung: Hintergrund: Grosse prospektive, rando-
misierte, kontrollierte klinische Studien haben für den intravi-
trealen Einsatz von Inhibitoren des vaskulären endothelialen 
Wachstumsfaktors (VEGF) klare Behandlungsvorgaben mit 
höchstem Evidenzniveau gegeben. Dies gilt für die häufigsten 
exsudativen Makulaerkrankungen (neovaskuläre, altersbezo-
gene Makuladegeneration, Makulaödem im Rahmen eines 
Diabetes oder eines venösen, retinalen Gefässverschlusses). 
Aufgrund zahlreicher Faktoren ist jedoch die Umsetzung einer 
optimalen, Evidenz basierten intravitrealen Therapie in kaum 
einem europäischen Land möglich. 
Material und Methode: Die folgende Übersicht zeigt die we-
sentlichsten Einflussfaktoren und deren grosse Variabilität in-
nerhalb von Europa, die eine adäquate Patientenbehandlung 
in ganz Europa erschweren. Um die Unterschiede zwischen 
einzelnen europäischen Ländern aufzuzeigen, wurden u. a. 
Fragebogen an Retinologen in Europa verschickt. 
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Zu den wesentlichsten limitierenden Faktoren gehören das in 
der Europäischen Union (EU) geltende Behandlungslabel für 
Ranibizumab und die national und teilweise regional gelten-
den Vorgaben für die Durchführung und Kostenerstattung der 
intravitrealen Therapie. Hinzu kommen teilweise regionale 
oder institutionelle Einschränkungen, die die Anzahl der int-
ravitrealen Injektionen reglementieren. Die Ergebnisse zei-
gen, dass es innerhalb von Europa Unterschiede gibt.
Resultate: Zu den wichtigen Unterschieden gehört die Dauer 
des nationalen Entscheidungsprozesses zur gesetzlichen Re-
gelung der Kostenerstattung. Dieser Prozess kann in einzel-
nen Ländern mehrere Jahre in Anspruch nehmen. Eine wei-
tere Einschränkung besteht in vielen Ländern in Hinblick 
darauf, welche Personen/Institutionen intravitreale Injektio-
nen durchführen darf und erstattet bekommt. Dies ist in den 
meisten Ländern an die Kostenerstattung durch das Gesund-
heitssystem gebunden. Besonders in osteuropäischen Län-
dern sind die Institutionen, denen intravitreale Injektionen 
erstattet werden, Budgets unterworfen, die adäquate evi-
denzbasierte Versorgung der Patienten weiter deutlich er-
schweren. Erhebliche Unterschiede sind zudem bei den je-
weils vorhandenen räumlichen Anforderungen und Auflagen 
an den Raum in dem die Injektion durchgeführt wird - von le-
diglich designiertem Injektionsraum bis zu vollwertigem 
Operationssaal - feststellbar. Hier zeigt sich innerhalb Euro-
pas eine deutliche Ost-West-Verteilung. Dieser Aspekt hat 
u. a. einen möglichen Einfluss auf die Sicherheit, aber auch 
auf die anfallenden Kosten und die Effizienz der Abläufe. 
Zum Teil sind die erheblichen Unterschiede in der Kostener-
stattung für eine intravitreale Injektion innerhalb Europas 
durch die Vorgaben für den Injektionsraum erklärbar. Der 
Preis für die Durchführung einer intravitrealen Injektion an 
Institutionen mit Kostenerstattung durch das Gesundheits-
system variiert innerhalb Europa von etwa 80 bis etwa 600 €. 
Jedoch variiert die Kostenerstattung für die intravitreale In-
jektion mitunter sogar regional oder in Abhängigkeit vom 
Versicherungssystem. 
Fast ubiquitär zeigt sich jedoch ein Mangel an finanziellen 
und personellen Ressourcen, um die Untersuchungs- und Be-
handlungsabläufe der Ära der intravitrealen Injektionen an-
zupassen. Dies ist von erheblichen Nachteil für die betroffe-
nen Patienten aber auch für viele behandelnde Ärzte.
Schlussfolgerung: Mit einer zunehmenden Anzahl betroffener 
und mit intravitrealen Injektionen behandelbarer Patienten 
wird der Druck für einen verbesserten Behandlungszugang 
steigen. Einheitlichere Vorgaben für die Durchführung und 
Kostenerstattung intravitrealer Injektionen innerhalb Europas 
oder zumindest auf nationaler Ebene wären wünschenswert. 
Leider ist ein Trend zur weiteren Regionalisierung feststellbar. 
Schlüsselwörter: intravitreale Injektion, Ranibizumab, Beva-
cizumab, IVOM, Kostenerstattung, Anti VEGF
Introduction
Intravitreal injections of vascular endothelial growth factor 
(VEGF) inhibitors have become the standard of care for most 
exudative macular diseases. So far, only ranibizumab and 
pegabtanib have been approved in the European Union (EU) 
by the European Medicines Agency. Due to best phase III clin-
ical study results, ranibizumab is the mostly used approved 
anti-VEGF drug in Europe. As of 2011 it is not only approved 
for the treatment of neovascular age-related macular degener-
ation (AMD), but also for diabetic macular edema (DME) and 
macular edema secondary to branch or central retinal vein oc-
clusions (BRVO/ CRVO) based on the results of large rand-
omized controlled clinical trials [1-5]. In any member country 
of the EU the approval by the European Medicines Agency is 
obligatory for any biotechnology drug. The approval is valid 
throughout the EU. Switzerland maintains an own approval 
process guided by the regulatory agency Swissmedic. In no 
European country bevacizumab is approved for intraocular 
injection. A preliminary approval in Italy has been withdrawn.
Limitations on the use of ranibizumab that are valid 
throughout the EU can be found on the official approval label 
[6].This label provides limitation to its use with regard to a 
“loading dose” at the initiation of treatment, retreatment cri-
teria as well as minimal treatment intervals. Details on the of-
ficial ranibizumab label are listed in table 1.
Of interest is that for only one of the approved indications 
(DME) the label is about consistent with treatment protocols 
of the large prospective clinical trials leading to the approval 
of the drug. Even for DME further large prospective clinical 
studies have shown in the meantime that monthly ranibi-
Fig. 1: Limiting reimbursement to hospitals Fig. 2: Co-payment for drug and/or intravitreal injection procedure
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zumab appears superior to the treatment indicated by the la-
bel/Restore study (ARVO 2011 - 6647 - D Brown - Ranibi-
zumab for Diabetic Macular Edema (DME): 24-Month Efficacy 
and Safety Results of RISE - a Phase 3 Randomized Controlled 
Trial) [3,6].So, if best evidence treatment protocols are used by 
ophthalmologists, their treatment is most of the time not ac-
cording to the official treatment guideline of the ranibizumab 
label in the EU. One major criticism on the treatment guide-
line of the label is that loss of vision is required for patients to 
be retreated. Currently available technologies (e. g. optical co-
herence tomography (OCT)) are a superior indicator for re-
treatment than loss of visual acuity. The PrONTO study out-
lined first that under anti-VEGF treatment in neovascular 
AMD patients visual function follows anatomic changes[7, 8]. 
The criticism on the label has found its way into retreatment 
recommendations by national ophthalmologic societies that 
clearly differ from the official label and recommended retreat-
ment whenever any disease activity is detected [9]. The only 
country in Europe, in which the current label allows monthly 
treatment for neovascular AMD – as in the Phase III studies – 
is Switzerland. 
However – beyond the EU drug label for ranibizumab – 
there are further limitations to the use of anti-VEGF drugs at 
the national level throughout Europe. To obtain a broad over-
view on the national limitations using anti-VEGF drugs a sur-
vey was sent to 50 retina specialists from 20 European coun-
tries. Key questions of the survey focused on reimbursement 
by the health care system, professional requirements to per-
form the intravitreal injection, specifications for the injection 
room and on the level of reimbursement for the intravitreal in-
jection at institutions that are reimbursed by the national 
health care system. 
The key information out of the responses of 23 retina spe-
cialists of 16 European countries was that there is limitation to 
anti-VEGF treatment access in any country. In addition, there 
is a large variability on how access to treatment is limited 
among the different countries. Within some countries (e. g. It-
aly, Spain, Portugal) there are even significant regional varia-
tions.
Only in selected countries additional qualifications of the 
treating ophthalmologist to perform the intravitreal injection 
are required. Among the exemptions is Germany, where sim-
ilar to an additional qualification to perform photodynamic 
therapy, an intravitreal injection training course as well as 
training in reading fluorescein angiographies are strongly rec-
ommended by the large ophthalmologic societies [10]. Oph-
thalmologists without this expertise have difficulties obtain-
ing reimbursement in the German health care system.
The first limitation for patients to get access to anti-VEGF 
treatments after approval of ranibizumab by the European 
Medicines Agency was in many European countries a signifi-
cant delay on national reimbursement decisions. The reim-
bursement decision is – different to the drug approval process 
– a national decision and includes in some countries long 
evaluation processes and price negotiations with the pharma-
ceutical industry. These price negotiations at the national 
level are the reason for some price variability between differ-
ent European countries. In general, delays due to lengthy 
price negotiations are more common in southern European 
countries. Reasons are lower attractiveness of southern Euro-
Fig. 3: Requirements for injection room
TabLe 1 
Label or ranibizumab (Lucentis®) by the 
European Medicines Agency6
Treatment of wet AMD
In wet AMD, the recommended dose for ranibizumab 
(Lucentis®) is 0.5 mg given monthly as a single intravitreal 
injection. This corresponds to an injection volume of 0.05 ml.
Treatment is given monthly and continued until maximum 
visual acuity is achieved, i.e. the patient`s visual acuity is 
stable for three consecutive monthly assessments performed 
while on ranibizumab treatment.
Thereafter, patients should be monitored monthly for visual 
acuity and activity of the disease.
Treatment is resumed when monitoring indicates loss of 
visual acuity due to wet aMD. Monthly injections should then 
be administered until stable visual acuity is reached again for 
three consecutive monthly assessments (implying a 
minimum of two injections). The interval between two doses 
should not be shorter than 1 month.
Treatment of visual impairment due to either 
DME or macular oedema secondary to RVO 
The recommended dose for Lucentis is 0.5 mg given as a 
single intravitreal injection. This corresponds to an injection 
volume of 0.05 ml.
Treatment is given monthly and continued until maximum 
visual acuity is achieved i.e. the patient’s visual acuity is 
stable for three consecutive monthly assessments performed 
while on ranibizumab treatment. If there is no improvement 
in visual acuity over the course of the first three injections, 
continued treatment is not recommended.
Thereafter patients should be monitored monthly for visual 
acuity.
Treatment is resumed when monitoring indicates loss of 
visual acuity due to DME or to macular oedema secondary 
to RVO. Monthly injections should then be administered until 
stable visual acuity is reached again for three consecutive 
monthly assessments (implying a minimum of two injec-
tions). The interval between two doses should not be shorter 
than 1 month.
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pean markets for the pharmaceutical industry and commonly 
stronger market regulations[11, 12]. The United Kingdom 
(UK) involves many stakeholders in the reimbursement deci-
sion process guided by the National Institute of Clinical Excel-
lence (NICE). Cost effectiveness is a key aspect in the NICE de-
cision process, which led during the price negotiations for 
ranibizumab in neovascular AMD to an agreement, in which 
the pharmaceutical industry covers the drug cost beyond the 
14th intravitreal injection [13]. A disadvantage of the process 
is the significant time delay until a final decision is taken [14].
The NICE guidance on ranibizumab for neovascular AMD to 
the National Health Service (NHS) in the UK took 1.5 years.
In many European countries the national health authori-
ties involved in the reimbursement process have added addi-
tional – not necessarily evidence based - limitations to the use 
of ranibizumab. 
The most relevant regulation at the national level in many 
European countries is however the limitation of reimburse-
ment of anti-VEGF therapy to specific institutions only. The 
most common differentiation is between private ophthalmol-
ogy practices and larger, mostly public hospitals. The survey 
revealed that in most European countries the reimbursement 
is limited to larger, mostly public clinics by the national or pri-
vate health care systems (Fig. 1). This is clearly a disadvantage 
for especially the elderly AMD population living in more rural 
regions. In some countries - e. g. Germany - bound to the sta-
tus of an institution but rather to the qualification of the treat-
ing ophthalmologist and the availability of an operating room 
for intravitreal injections. Only in the Neatherlands reim-
bursement of intravitreal injections is soley provided for pri-
vate practices. 
The key problem in many European countries for many pa-
tients with exudative macular disease to gain adequate access 
to evidence based best treatment is that institutions, where in-
travitreal anti-VEGF therapy is covered by the health care sys-
tem, are submitted to further restrictions. In many southern 
and eastern European countries drug cost and/or injection 
procedure cost fall under a clinic budget that permits only 
limited use of in particular ranibizumab. The subsequent con-
sequences to reduce cost are the splitting of ranibizumab or 
the off-label use of bevacizumab. In some countries (e. g. Hun-
gary) institutions providing intravitreal injections are submit-
ted to a regulated and limited number of surgical procedures 
including intravitreal injections. A further phenomenon are 
even counterproductive incentives. Some Italian Ophthalmol-
ogy department budgets are influenced by the waiting time for 
new glasses and cataract surgery rather than the waiting time 
to treatment for a patient with neovascular AMD. This situa-
tion of extensive patient waiting lists for reimbursed anti-
VEGF treatment leads to patients being treated with signifi-
cant delay (having had further vision loss in the meantime) or 
being forced into private practice without being reimbursed 
by the health care system. 
Another aspect is the reimbursement of the intravitreal in-
jection as surgical procedure. In many countries (e. g. Austria, 
Finnland, Spain, Portugal…) reimbursement of the injection 
procedure falls within an overall clinic budget. So, there is no 
incentive in increasing the number of injections and reducing 
the waiting time for affected patients. This situation is not only 
a burden for the patients but also for the treating ophthalmol-
ogists, who have to work in suboptimal settings and have to 
compensate for an increasing workload. Especially in coun-
tries with a privately organized health care system co-pay-
ments for injection procedures are not uncommon (Fig. 2). 
In Germany currently no specific billing code exists for the 
intravitreal injection procedure. The co-payment varies there-
fore depending on the treating physician, the private health 
care coverage plan, specific contracts between health care 
providers and physicians networks and in some cases even on 
the anti-VEGF drug used. In addition, follow-up visits are not 
always reimbursed. Due to the high number of injections and 
follow-up visits required, most patients are confronted with 
additional costs – despite official coverage/reimbursement –, 
which can be a major burden for patients and subsequently 
leads to reduced compliance and worse functional outcomes.
The compensation for the intravitreal injection as surgical 
procedure varies significantly within Europe. Table 2 outlines 
the results of the conducted survey. It provides only a limited 
overview since even at the national level there is a large varia-
bility due to various factors and since the survey is based on 
relatively few responses (n = 23). 
Some variation can be explained by national requirements 
for the injection rooms. Commonly the national health au-
thorities outline the requirements for an injection room and 
these are further communicated by guidelines of the national 
ophthalmologic societies. The requirements range from a des-
ignated room – without any further specifications – up to a 
fully equipped operating room with laminar airflow. Figure 3 
outlines in which European countries - with minor national 
variations - a designated room or a fully equipped operating 
room is required.
Some east-west distribution throughout Europe appears 
evident. The national requirements for injection room have 
significant implications. 
The first one is safety. Publications on the rate of endoph-
thalmitis (excluding series due to improper drug preparation 
by compounding pharmarcies) in large injection clinics in the 
United States (US) – where just designated rooms are used for 
the injection procedure - are at the range of 1 endopthalmitis 
TabLe 2 
Compensation for intravitreal injection 
procedure (without drug) – exchange 
rate 12/11 (where applicable)
 Country averaged cost (€)
Netherlands 600
Switzerland 510
Germany 300
Sweden 220
Poland 200
France 145
Czech Rep. 140
Italy 115
Hungary 100
Belgium 80
Others (Austria, Finnland, 
Spain, Portugal) Budget
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every 1200 – 5000 intravitreal injections [15, 16, 17]. A recent 
retrospective study analyzing endophthalmitis cases follow-
ing surgical procedures and intravitreal injections in a desig-
nated room showed a higher risk for endophthalmitis with 
worse outcomes for endophthalmitis secondary to intravitreal 
injections outside an operating room [16]. In addition a large 
multicenter clinical trials conducted in the US and Europe in-
dicated an overall lower risk at European centers (ARVO 2011 
- 6647 - D Brown - Ranibizumab for Diabetic Macular Edema 
(DME): 24-Month Efficacy and Safety Results of RISE - a Phase 
3 Randomized Controlled Trial). Our own experience at a 
swiss eye clinic – submitted to the highest standards (OR with 
laminar airflow) – had only a single culture negative endoph-
thalmitis in more than 20000 injections since 2006. Obviously 
the current data does not prove that higher hygienic standards 
for an injection room are necessarily associated with a lower 
risk for endophthalmitis, but many of the multiple factors 
(mask over mouth and nose, sterile gloves…) potentially asso-
ciated with a lower risk for endophthalmitis are part of the re-
quirements of running an operating room for intraocular surgery. 
The second one is cost and patient flow. The expenses on 
building and running an operating room with a high hygienic 
standard are extensive. Just the operating room and energy 
cost plus the amortization sum up to 12.5 € per minute accord-
ing to Albrecht and Toepfer [18]. In addition the operating 
room has to have sufficiently qualified staff. In most clinics op-
erating rooms built prior to the “intravitreal injection era” are 
used for intravitreal injections. This leads on the one hand to 
competitive displacement of other surgical procedures, on the 
other hand these operating rooms are often not ideally located 
for highly frequented injection clinics. This is a significant 
draw back for patient flow and a limiting factor in any effort in 
reducing the patients time in clinic. 
As shown there are numerous obstacles in providing best 
evidence care to patients with neovascular AMD, with DME 
and edema secondary to RVO. A key obstacle in all countries 
of the EU is the current label for ranibizumab. Additional var-
iable limitations occur at the national level. Even though in all 
European countries treatment with ranibizumab is approved 
and mostly reimbursed, significant obstacles prevent many 
patients from getting treatment on time, in an adequate set-
ting and according to the best evidence treatment regimen. In 
the context of the ongoing debate on the risk for endophthal-
mitis using different anti-VEGF drugs, one has to reconsider 
under which conditions the intravitreal injection is per-
formed. There is increasing evidence that the risk for endoph-
thalmitis is lowest in a fully equipped operating room. This 
however goes together with significantly higher cost, worse 
patient flow and longer patient waiting time.
There is clearly need for improvement throughout Europe 
to provide affected patients with better and closer to best evi-
dence care. It is likely that the rapidly growing patient popula-
tion requiring intravitreal injections will increase pressure on 
all stakeholders. 
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